Related references
Note: Only part of the references are listed.Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells
J Wharton et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors
I Matot et al.
CHEST (2004)
Protein kinase C inhibits BK(Ca) channel activity in pulmonary arterial smooth muscle
SA Barman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension
A Sebkhi et al.
CIRCULATION (2003)
cAMP activates BKCa channels in pulmonary arterial smooth muscle via cGMP-dependent protein kinase
SA Barman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2003)
Potassium (BKCa) currents are reduced in microvascular smooth muscle cells from insulin-resistant rats
C Dimitropoulou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension
J Nagamine et al.
CRITICAL CARE MEDICINE (2000)
Involvement of cGMP-dependent protein kinase in the relaxation of ovine pulmonary arteries to cGMP and cAMP
SN Dhanakoti et al.
JOURNAL OF APPLIED PHYSIOLOGY (2000)
cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BKCa channel activity in coronary artery smooth muscle cells
RE White et al.
CIRCULATION RESEARCH (2000)
Share Paper
